Senior Patent Attorney

Patent drafting, medical devices, biotech, wound healing, start-ups, universities


Dr Lisa Brown (Lady Lisa Markham) is a European Patent Attorney and a UK Chartered Patent Attorney.  Lisa is a Fellow of the British Toxicology Society and the Chairwoman of a University spin-out company and is also a member of the External Advisory Board of Medical Technologies Innovation and Knowledge Centre in Regenerative Medicine.

After leaving a successful career in science Lisa entered the patent profession in 1995. With more than 20 years’ experience, Lisa enjoys devising and implementing IP strategies for clients to ensure robust protection and commercially valuable biotechnology and medical device inventions.  She has worked with a variety of clients at different levels, from inventors to devise experiments to support patent filings to senior management to advise on FTO, due diligence and acquisitions.  Her specialty UK client base is Universities, spin-outs and SMEs.

A widely published academic, Lisa has a BSc in Biochemistry and Toxicology from the University of Surrey and completed an industrial year at the National Vegetable Research Station working with plant disease resistance before completing a PhD in mammalian metabolism and toxicology from the University of Surrey in conjunction with ICI’s Pharmaceutical Division.  She conducted post-doctoral research at the Epidemiology Department of ICI in risk assessment, and subsequently became a toxicology manager in Occupational Health at ICI’s Agrochemical Division being responsible for reviewing and setting “safety limits” for human exposure to pesticides.


  • BSc (hons) Biochemistry and Toxicology
  • PhD Biochemistry and Metabolism
  • Chartered UK Patent Attorney
  • European Patent Attorney


  • Tiptoeing-around-restrictions-in-biotechnology-inventions-a-practitioner’s-experience.
  • Guest speaker at University of Leeds in graduate biotechnology programme.
  • “Correlations between bioassay dose-level, mutagenicity to Salmonella, chemical structure and sites of carcinogenesis among 226 chemicals evaluated for carcinogenicity by the U.S. NTP”. L P Brown and J A Ashby, Mutation Research Letters, 224, 67-76, 1990.
  • “Teratogenicity of phenylhydantoins in an in vitro system: Molecular orbital-generated quantitative structure-toxicity relationships”. L P Brown, D F V Lewis, O P Flint and G G Gibson, Xenobiotica19(12):1471-81, 1990.
  • “Do rats comply with EPA policy on cancer risk assessment for formaldehyde?” L P Brown Regulatory Toxicology and Pharmacology 10(2): 196-200, 1989.
  • “Localization and identification of cytochrome P-450 in differentiating rat embryo cells in vitro and in foetal tissue in vivo by immunocytochemistry”. L P Brown, J R Foster, O P Flint and G G Gibson, Toxicology in Vitro3(4):245-52, 1989.
  • Inducibility and functionality of rat embryonic/foetal cytochrome P-450: A study of differentiating limb-bud and mid-brain cells in vitro”. L P Brown, J R Foster, O P Flint and G G Gibson, Toxicology in Vitro 3(4):253-60, 1989.
  • “In vitro metabolism of teratogens by differentiating rat embryo cells” L P Brown, D F V Lewis, O P Flint and G G Gibson, Food and Chemical Toxicology24(6-7):737-42, 1986.
  • “Tobacco-mosaic-virus-induced increase in abscisic-acid concentration in tobacco leaves: Intracellular location in light and dark-green areas, and relationship to symptom development” J R Whenham, R S S Fraser, L P Brown and JA Payne, Planta 168(4);592-98, 1986.


BL/O/058/10 Excluded Fields, which has subsequently been adopted into the UK Manual of Patent Practice,


  • Biotechnology, wound healing, regenerative medicine, therapeutics and cosmetics, diagnostic markers, gene therapy, screening techniques, transplant products, dental products, transgenic plants and animals and medical devices.


  • Patent drafting and prosecution, due diligence, freedom to operate, IP strategy.